Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
As it is clearly stated in the review by Gottstein and Cooke,1 we consider it unethical to withhold or delay high dose intravenous immunglobulin (IVIG) treatment in infants with haemolytic disease of the newborn. Since the study we did in 1995,2 we have treated 129 patients with Coomb’s positive haemolytic disease of the newborn, with the same method and had to …